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Abstract
To find a new biomarker of Tay-Sachs disease and Sandhoff disease. The lyso-GM2 ganglioside (lyso-GM2) levels in the brain
and plasma in Sandhoff mice were measured by means of high performance liquid chromatography and the effect of a
modified hexosaminidase (Hex) B exhibiting Hex A-like activity was examined. Then, the lyso-GM2 concentrations in human
plasma samples were determined. The lyso-GM2 levels in the brain and plasma in Sandhoff mice were apparently increased
compared with those in wild-type mice, and they decreased on intracerebroventricular administration of the modified Hex
B. The lyso-GM2 levels in plasma of patients with Tay-Sachs disease and Sandhoff disease were increased, and the increase
in lyso-GM2 was associated with a decrease in Hex A activity. Lyso-GM2 is expected to be a potential biomarker of Tay-Sachs
disease and Sandhoff disease.
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Introduction
Hydrolysis of GM2 ganglioside (GM2) is catalyzed in lysosomes
by b-hexosaminidase (Hex, EC 3.2.1.52) A, and a non-enzymic
factor, GM2 activator (GM2A), is essentially required in the
catabolic reaction in vivo. Hex A is a heterodimeric protein
composed of an a- and a b-subunit encoded by the HEXA and
HEXB genes, respectively, and GM2A is encoded by the GM2A
gene. Defects in any of these three genes result in excessive
accumulation of GM2 and related glycolipids in lysosomes, mainly
those of neural cells, leading to a rare neurodegenerative disorder,
GM2 gangliosidosis, which comprises three biochemically different
disorders: (a) Tay-Sachs disease (B variant, MIM 272800) results
from mutations of the HEXA gene, being associated with deficient
Hex A activity; (b) Sandhoff disease (0 variant, MIM 268800) is
due to mutations of the HEXB gene, being associated with
deficient Hex A and Hex B (a homodimer of the b-subunit)
activities; and (c) GM2A deficiency (AB variant, MIM 272750) is
an extremely rare genetic disease caused by mutations of the
GM2A gene, being characterized by lysosomal storage of GM2
despite normal Hex A activity. GM2 gangliosidosis exhibits a wide
clinical spectrum from the early-onset severe ‘‘infantile type’’ to
the late-onset mild ‘‘attenuated type’’. The clinical, genetic, and
biochemical aspects of this disease have been reviewed [1].
So far, little effective therapy for GM2 gangliosidosis has been
developed [2–5]. However, recently the therapeutic potential of
enzyme replacement therapy (ERT) with recombinant human
Hex A and modified Hex B, both of which exhibit GM2-
degrading activity, has been reported [6–8], and they are
promising as new enzymes for ERT for Tay-Sachs disease and
Sandhoff disease. Considering this, a useful biomarker for the
diagnosis of and monitoring of the response to therapy for these
diseases is strongly required.
In this study, we paid attention to lyso-GM2 ganglioside (lyso-
GM2), a derivative of GM2 that recently attracted interest as a
possible pathogenetic agent for these diseases, and measured the lyso-
GM2 levels in the brain and plasma in Sandhoff mice, and examined
the effect of intracerebroventricularly administrated modified Hex B
on the degradation of the lyso-GM2 accumulated in the brain and
plasma. Then, we determined the levels of lyso-GM2 in plasma
samples from patients with various types of GM2 gangliosidosis
including Tay-Sachs disease, Sandhoff disease, and GM2A deficiency.
Materials and Methods
Ethics
The human blood samples were obtained before 1999 with
verbal consents from the participants and/or parents of the infants
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Committee of Meiji Pharmaceutical University discussed about
the usage of these samples for measuring the concentration of lyso-
GM2 and activity of hexosaminidase, and approved it (ID: 1908)
because at present the written consent from the participants and/
or parents of the infants cannot be obtained as they are dead and/
or their present addresses are unknown but this study is thought to
be useful for medicine and these samples are essentially required
for this study.
This study involving animals was approved by the Animal
Experiment Committee of the University of Tokushima (ID:
10106), and the experiments were performed according to
protocols approved by the committee.
Materials
Lyso-GM2, as a standard for both high performance liquid
chromatography (HPLC) and Matrix-Assisted Laser Desorption/
Ionization-Time of Flight-Mass Spectrometry (MALDI-TOF-
MS), was purchased from TAKARA BIO Inc. (Shiga, Japan).
GM2, as a standard, for thin layer chromatography, and 4-
methylumbelliferyl-N-acetyl-b-D-glucosaminide (MUG), for de-
termining Hex A and Hex B activities, were obtained from Sigma
Chemical Co. (St. Louis, MO). 4-Methylumbelliferyl-6-sulfo-b-D-
glucosaminide (MUGS), for measuring Hex A activity, was
purchased from Calbiochem (San Diego, CA). o-Phthalaldehyde
(OPA), for derivatizing lyso-GM2, was purchased from Nacalai
Tesque (Kyoto, Japan). 2,5-Dihydroxybenzoic acid (2,5-DHB) and
Peptide calibration standard II for MALDI-TOF-MS were
purchased from Bruker Daltonics Inc. (Billerica, MA). All other
chemicals used were of analytical grade. A genetically engineered
HEXB encoding a chimeric human b-subunit containing a partial
amino acid sequence of the a-subunit (bD452N, bL453R, and
bRQNK312-315 GSEP) was designed by structure-based homol-
ogy modeling, and was introduced into Chinese hamster ovary
cells (RIKEN BIORESOURCE CENTER CELL BANK, Tokyo,
Japan), and a modified Hex B was produced and purified as
described previously [4].
Human plasma samples
Plasma samples for measurement of the MUG-degrading and
MUGS-degrading activities, and the lyso-GM2 levels were
obtained from two patients with Sandhoff disease (one infantile
[9] and one adult [10] case) and their parents, five patients with
Tay-Sachs disease (five infantile cases) and their parents, one
patient with GM2A deficiency (one infantile case) [11], and 48
control subjects.
Measurement of lyso-GM2 in mouse brain and plasma
Sandhoff (Hexb
2/2) mice (C57BL/66129sv) were kindly
provided by Dr. Richard L. Proia (NIDDK, National Institute
of Health). Ten-week-old Sandhoff mice (n=3) were intracer-
ebroventricularly injected with a modified Hex B (20 mmol/h/
25 mL), and then sacrificed 1 week after the injection, and their
brains and plasma samples were obtained. Untreated Sandhoff
mice (n=5) and wild-type (C57BL/6) ones (n=5) were also used
in this experiment. Before removing their brains, the mice were
perfused with phosphate-buffered saline (PBS), pH 7.4. Extrac-
tion of lyso-GM2 from the brain and plasma was performed
according to our method for measurement of globotriaosyl-
sphingosine [12,13] with slight modifications. Briefly, to 10 mLo f
a brain homogenate, 120 mL of chloroform/methanol (1/2, v/v)
was added, and then the mixture was centrifuged for 5 min at
1,0006g. The supernatant was placed in another tube. The
residue was re-extracted with 120 mL of chloroform/methanol
(2/1, v/v). To the combined supernatants, 120 mL of chloroform
and 72 mL of water were added, and then the extract was
centrifuged for 5 min at 2,0006g and the upper phase was
removed. To the lower phase, 360 mL of methanol/water (2/1,
v/v) was added, followed by mixing, and then the extract was
centrifuged for 5 min at 9,0006g. Then, the combined upper
phases were dried and taken up in 250 mL of water, and the water
phase was extracted twice with 250 mL of water-saturated 1-
butanol. The butanol phase was dried and dissolved in 50 mLo f
methanol, and then lyso-GM2 in the solution was derivatized
with 25 mL of OPA reagent (pH 11). The OPA-derivatized lyso-
GM2 was separated by HPLC, and then measured by means of
fluorescence detection (excitation wavelength: 340 nm, and
emission wavelength: 435 nm). Chromatographic separation
was carried out on a Unison UK-C18 column (15064.6 mm
I.D., 3 mm; Imtakt, Kyoto, Japan) with a mobile phase of
tetrahydrofuran/methanol/water (9/31/40, v/v/v, flow rate
1.0 mL/min). The column oven was kept at 40uC during the
procedure.
For plasma lyso-GM2 extraction, 25 mL of plasma was used as a
sample, and the extraction procedure was carried out in the same
manner as in the case of brain lyso-GM2 except for the use of two
volumes of the organic solvents. A calibration curve for lyso-GM2
was prepared by the addition of authentic lyso-GM2 to a normal
brain homogenate or plasma.
Identification of lyso-GM2 by MALDI-TOF-MS
To identify lyso-GM2, the crude lipid extract was applied to
pre-coated high performance thin-layer chromatography
(HPTLC)-silica gel plates (1006200 mm; E. Merck, Darmstadt,
Germany). Then, lyso-GM2 was extracted twice from the
HPTLC plates with 200 mL of water-saturated 1-butanol, and
the butanol phase was dried. For both MS and MSMS
measurements, dried samples were dissolved in 10 mL of the
matrix solution (10 mg/mL 2,5-DHB in 50% methanol) and
4 mL of the resultant solution was loaded onto a sample plate with
384 sample positions, allowed to dry and then crystallized for
60 min at room temperature. Positive ion MALDI-TOF-MS and
MS/MS spectra of the lyso-GM2 were obtained by ultrafleX-
tream (Bruker Daltonics Inc., Billerica, MA). In order to calibrate
the mass spectra of the lyso-GM2, Peptide calibration standard II
was used.
Measurement of GM2 in mouse brain
Crude glycolipids were extracted from tissue homogenates
according to the method previously described [11]. Briefly,
crude glycolipids were extracted with a mixture of chloroform/
methanol/water (4/8/3, v/v/v) three times. This solvent
mixture containing the extracted crude glycolipids was
collected and then dried under a stream of nitrogen. The
crude glycolipids were resolved in chloroform/methanol/water
(60/30/4.5, v/v/v), the concentration being 0.5 mg tissue
weight/mL of the reagent. To identify GM2, the crude
glycolipids were applied to precoated HPTLC-silica gel plates
(1006200 mm; E. Merck). The developing solvent used was
chloroform/methanol/water (65/25/4, v/v/v). Glycosphingo-
lipids containing GM2 were visualized with orcinol reagent.
Then, HPTLC-immunostaining with an anti-GM2 monoclonal
antibody [14] was performed according to the method
described previously [11], and the amounts of GM2 were
determined by densitometric scanning with a luminescent
image analyzer, LAS 4000, equipped with Multi Gauge Ver3.X
(FUJI FILM, Tokyo, Japan).
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The lyso-GM2 levels in human plasma samples were deter-
mined according to the method described under ‘‘Measurement of
lyso-GM2 in mouse brain and plasma’’.
Enzyme assays
Total Hex (mainly Hex A and Hex B) and Hex A activities in
human plasma samples were fluorometrically determined with
MUG and MUGS as substrates, respectively, according to the
method described previously [11].
Statistical analyses
Statistical analyses were performed by means of Student’s t-test.
Values were considered statistically significant at P,0.05.
Results
Detection of lyso-GM2 in mouse brain
A lipid fraction including lyso-GM2 was obtained from brain
tissues of mice and the free amine moiety of lysosphingolipids was
labeled with OPA. Then, the lysosphingolipids were separated by
HPLC, and the lyso-GM2 levels in the brain tissues from the
Sandhoff mice treated and not treated with the modified Hex B
and the wild-type ones were determined. Peak identification was
performed by comparison with that of authentic lyso-GM2. The
lyso-GM2 level was determined from the calibration curve
obtained by plotting the lyso-GM2 peak area against the
concentration.
Fig. 1 shows HPLC-chromatograms of lyso-GM2 in the brain
tissues. A high peak was observed for the brain of the untreated
Sandhoff mouse, the peak being apparently decreased for the
brain of the enzyme-treated Sandhoff mouse. No peak corre-
sponding to lyso-GM2 could be detected for the brain of the wild-
type one.
MALDI-TOF-MS analysis was performed to confirm that the
abnormal structure was lyso-GM2 accumulated in the brain tissues
of Sandhoff mice. The spectrum exhibited a main [M+H]
+
molecular ion signal at m/z 1118, and MALDI-TOF-MS analysis
revealed that the sequence ions exhibited by the accumulated
substrates in the Sandhoff mouse brain were identical to those
derived from authentic lyso-GM2. The corresponding fragmenta-
tion scheme is shown in Fig. 2.
Lyso-GM2 levels in the brain and plasma of Sandhoff mice, and
effect of the modified Hex B on cleavage of lyso-GM2
accumulated
Fig. 3 shows the lyso-GM2 levels in the brain and plasma of
mice. Brain tissues from the wild-type mice exhibited lyso-GM2
levels below the detection level of 0.02 nmol/g. However, those in
the Sandhoff mice were apparently increased to 5.660.8 nmol/g
(mean6SD). The lyso-GM2 levels in the brain tissues from the
Sandhoff mice treated with the modified Hex B decreased to
0.960.4 nmol/g (Fig. 3a) compared with those in the untreated
Sandhoff mice.
Although the lyso-GM2 levels in the plasma of the wild-type
mice were below the detection level of 1.0 nmol/L, those in the
Sandhoff mice were apparently increased (9.462.1 nmol/L,
mean6SD). The plasma lyso-GM2 levels in the Sandhoff mice
treated with the modified Hex B were decreased (5.263.5 nmol/
L, mean6SD), compared with those in the untreated Sandhoff
mice except for one case (9.1 nmol/L). The results of the plasma
lyso-GM2 analysis are summarized in Fig. 3b. The results are
correlated with those in the case of brain lyso-GM2.
GM2 levels in the brain of Sandhoff mice and effect of the
modified Hex B on cleavage of GM2 accumulated.
Figure 1. HPLC-chromatograms of lyso-GM2 in the brain. A wild-type mouse (W), an untreated Sandhoff mouse (S), and a Sandhoff mouse
treated with the modified Hex B (S+E). Arrows indicate the peak of lyso-GM2.
doi:10.1371/journal.pone.0029074.g001
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mice, and the Sandhoff ones treated and not treated with the
modified Hex B. Brain tissues from the wild-type mice exhibited
GM2 levels below 10 ng/mg. On the other hand, the brain GM2
levels in the Sandhoff mice were apparently increased
(312642 ng/mg, mean6SD). The GM2 levels in the Sandhoff
mice treated with the modified Hex B were decreased
(109645 ng/mg, mean6SD), compared with those in the
untreated Sandhoff mice. The results were correlated with those
in the case of brain lyso-GM2, although the effect of the modified
Hex B on cleavage of the GM2 accumulated was lower than that
in the case of lyso-GM2.
Lyso-GM2 levels and Hex activities in human plasma
Table 1 summarizes the lyso-GM2 concentrations, and MUG-
and MUGS-degrading activities in plasma samples from patients
with Sandhoff disease, Tay-Sachs disease and GM2A deficiency,
their parents, and controls. Plasma samples from the control
subjects exhibited lyso-GM2 levels below 2.0 nmol/L. The plasma
lyso-GM2 levels in the patients with Sandhoff disease and Tay-
Sachs disease were apparently increased, i.e., an infantile Sandhoff
case, 12.7 nmol/L, an adult Sandhoff one, 2.9 nmol/L, and an
infantile Tay-Sachs one 32.765.1 nmol/L (means6SD, n=5).
On the other hand, the plasma lyso-GM2 level in the patient with
GM2A deficiency was normal (, 2.0 nmol/L). The parents of
Sandhoff disease and Tay-Sachs disease patients exhibited normal
lyso-GM2 levels as expected.
The Sandhoff patients exhibited decreases in both the MUG-
and MUGS-degrading activities, which reflected the combined
deficiency of Hex A and Hex B. The enzyme activities in the
adult case were moderately higher than those in the infantile
one. The decrease in enzyme activity was correlated with an
increase in lyso-GM2. All of the infantile Tay-Sachs patients
exhibited a decrease in MUGS-degrading activity, which
reflected a specific deficiency of Hex A. The patients with
GM2 activator deficiency exhibited normal enzyme activities for
both Hex A and Hex B.
Discussion
Although the details of the pathogenetic mechanisms leading to
sphingolipidoses have not been clarified yet, it is likely that
excessive accumulation of sphingolipids causes cellular dysfunc-
tion, induction of cytokines and a defect of autophagy. Another
possible pathogenetic mechanism may be the formation of
lysosphingolipids. Galactosylsphingosine and glucosylsphingosine
are known to accumulate in neural cells of patients with Krabbe
disease and Gaucher disease, respectively [15,16]. Furthermore, it
has been reported that not sphingolipids but lysosphingolipids
induce apoptosis of mouse neuroblastoma Neuro2a cells [17], and
apoptosis has actually been found in neural tissues of mouse
models of GM2 gangliosidosis, and patients with Tay-Sachs
disease and Sandhoff disease [18]. Lysosphingolipids are cytotoxic
and may well be the pathogenetic agent for the neural
degeneration in these diseases.
In GM2 gangliosidosis, lyso-GM2 was found in the brain tissues
of patients with Tay-Sachs disease and Sandhoff disease as well as
GM2 [19–22]. The origin of this lyso-GM2 is obscure, but an
Figure 2. MALDI-TOF-MS spectra of lyso-GM2. Structure of lyso-GM2 (top) and its spectra obtained for the brain of a Sandhoff mouse (bottom).
doi:10.1371/journal.pone.0029074.g002
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loss of Hex A activity and may be related to the pathophysiologies
of these diseases.
Biomarkers of Tay-Sachs disease and Sandhoff disease useful for
diagnosis and assessment of the effect of enzyme replacement
therapy, which will be introduced clinical medicine in the near
future, are now strongly required. So, we paid attention to lyso-
GM2 and examined the lyso-GM2 level in brains of Sandhoff mice
and the effect of the modified Hex B on cleavage of the lyso-GM2
accumulated. Our investigation revealed that the brain lyso-GM2
level in Sandhoff mice was increased and the intracerebroven-
tricular injection of the enzyme apparently decreased it. The effect
of the enzyme on cleavage of lyso-GM2 was more impressive
compared with that in the case of GM2. As lyso-GM2 is more
hydrophilic than GM2, which aggregates as a component of
cellular membranes, the lyso-GM2 level would be more strongly
influenced by the administration of the hydrophilic enzyme than
that of GM2.
Then, we established an assay method for measuring plasma
lyso-GM2 with HPLC, and determined the plasma lyso-GM2
levels in mice. The plasma lyso-GM2 levels in Sandhoff mice were
apparently increased and they decreased on administration of the
enzyme. The assay procedure is easy and authentic lyso-GM2, as a
standard, which is necessary for quantifying plasma lyso-GM2, is
commercially obtained, although it is difficult to obtain a proper
authentic GM2 as a standard for measuring plasma GM2 levels by
means of tandem mass spectrometry because GM2 purified from
animal tissues usually has heterogeneous fatty acids.
Finally, we examined the lyso-GM2 levels in human plasma.
The results were well correlated with those of the animal
experiment, and it was revealed that the plasma level of lyso-
GM2 was increased in patients with Tay-Sachs disease and
Sandhoff disease. The increase in lyso-GM2 was associated with a
decrease in Hex A activity. A patient with GM2A deficiency
exhibited a normal level of lyso-GM2. As a patient with GM2A
deficiency has a sufficient amount of Hex A, it may degrade
hydrophilic lyso-GM2 without GM2A.
In conclusion, lyso-GM2 is expected to be a potential biomarker
of Tay-Sachs disease and Sandhoff disease.
Figure 3. Lyso-GM2 levels in the brains and plasma of mice. Lyso-GM2 levels in brain tissues (A) and plasma (B). Wild-type mice (W,¤),
untreated Sandhoff mice (S,&), and Sandhoff mice treated with the modified Hex B (S+E,m). Each line indicates the mean6SD. *P,0.05 (t-test).
doi:10.1371/journal.pone.0029074.g003
Figure 4. GM2 levels in the brains of mice. GM2 levels in brain
tissues of wild-type mice (W,¤), untreated Sandhoff mice (S,&), and
Sandhoff mice treated with the modified Hex B (S+E,m). Each line
indicates the mean6SD. *P,0.05 (t-test).
doi:10.1371/journal.pone.0029074.g004
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Sandhoff disease Patient 1 1 y M 17 5 12.7 [9]
Patient 2 31 y M 42 5 2.9 [10]
Parent 1-1 unknown M 309 34 ,2.0 -
Parent 1-2 unknown F 357 41 ,2.0 -
Tay-Sachs disease Patient 3 1 y F 552 2 39.9 -
Patient 4 1 y F 533 2 29.7 -
Patient 5 1 y M 382 2 26.4 -
Patient 6 1 y M 494 2 30.1 -
Patient 7 2 y M 281 1 32.6 -
Parent 3-1 31 y M 542 27 ,2.0 -
Parent 3-2 33 y F 513 31 ,2.0
Parent 4-1 unknown M 347 30 ,2.0 -
Parent 4-2 unknown F 478 26 ,2.0 -
Parent 5-1 31 y F 1.12610
3 35 ,2.0 -
GM2A deficiency Patient 8 1 y M 1.42610
3 81 ,2.0 [11]
Control (n=48) M/F 7096302 58614 ,2.0
Patient 1, and parents 1-1 and 1-2 are from the same family; patient 3, and parents 3-1 and 3-2 are from the same family; patient 4, and parents 4-1 and 4-2 are from the
same family; and patient 5, and parent 5-1 are from the same family.
doi:10.1371/journal.pone.0029074.t001
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